Wake Forest University Baptist Medical Center
Hematology and Oncology fellowship · Winston-Salem, NC · Atrium Health Wake Forest Baptist programs · Program website
Internal Medicine residency here · Other fellowships: Rheumatology · Cardiovascular Disease · Gastroenterology · Pulmonary and Critical Care · Nephrology · Infectious Disease · Endocrinology, Diabetes, and Metabolism · Geriatric Medicine · Allergy and Immunology
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Atrium Health Wake Forest Baptist's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
Hematology and Oncology at Atrium Health Wake Forest Baptistshared by every program there, not this program's own
Institution-level: all hematology and oncology publications from Atrium Health Wake Forest Baptist and affiliated institutions, since 2022. Updated 2026-11-09; refreshed daily.
Works per year · * 2026 so far
Hematology and Oncology research topics at Atrium Health Wake Forest Baptist
Papers in the window; each links to the list on OpenAlex.
- Myeloproliferative Neoplasms: Diagnosis and Treatment 55
- Acute Myeloid Leukemia Research 48
- Cancer survivorship and care 37
- Multiple Myeloma Research and Treatments 35
- Cancer Immunotherapy and Biomarkers 32
- Glioma Diagnosis and Treatment 28
- Pancreatic and Hepatic Oncology Research 18
- Renal cell carcinoma treatment 15
Most cited at Atrium Health Wake Forest Baptist since 2024
All hematology and oncology papers there on OpenAlex
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myelomaSurbhi Sidana et al. · Blood · 2025 · PubMed · cited 36
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K. Rampal et al. · Nature Medicine · 2025 · PubMed · cited 69
- International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J. Costa et al. · Leukemia · 2025 · PubMed · cited 89
- Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana et al. · Blood · 2024 · PubMed · cited 162
- Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Z. Badros et al. · Blood · 2024 · PubMed · cited 72
- Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A. Philip et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 54
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPTPaolo Tarantino et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 48
- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current eraAnand Ashwin Patel et al. · Blood Advances · 2024 · PubMed · cited 38
- Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation studyFarhad Ravandi et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2024 · PubMed · cited 41
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S. Callander et al. · Blood Cancer Journal · 2024 · PubMed · cited 36
Add to your program's websitea badge, your paper list, a feed
For program directors and coordinators. Both update with the site and need no account.
<a href="https://openprograms.org/programs/wake-forest-university-baptist-medical-center-heme-onc"><img src="https://openprograms.org/programs/wake-forest-university-baptist-medical-center-heme-onc/badge.svg" alt="Wake Forest University Baptist Medical Center Hematology and Oncology fellowship on OpenPrograms" height="20"></a>Something wrong or missing on this page? Use the correction form below; changes show up in both.